Clinical  	Clinical  	 JJ	B-NP
perspective 	perspective 	 NN	I-NP
:  	:  	 :	O
biomarkers  	biomarkers  	 FW	B-NP
in  	in  	 FW	O
pulmonary  	pulmonary  	 FW	B-NP
arterial  	arterial  	 FW	I-NP
hypertension  	hypertension  	 FW	I-NP
Biomarkers  	Biomarkers  	 NNP	I-NP
are  	are  	 VBP	O
objectively  	objectively  	 RB	O
measured  	measured  	 VBN	B-NP
characteristics  	characteristics  	 NNS	I-NP
used  	used  	 VBN	O
as  	as  	 IN	O
indicators  	indicators  	 NNS	O
of  	of  	 IN	O
disease  	disease  	 NN	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
and  	and  	 CC	O
as  	as  	 IN	O
surrogate  	surrogate  	 JJ	O
endpoints  	endpoints  	 NN	B-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
six-minute  	six-minute  	 JJ	B-NP
walk  	walk  	 NN	I-NP
test  	test  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
widely  	widely  	 RB	O
used  	used  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
trial  	trial  	 NN	B-NP
endpoint  	endpoint  	 NN	I-NP
in  	in  	 IN	O
pulmonary  	pulmonary  	 FW	B-NP
arterial  	arterial  	 FW	I-NP
hypertension  	hypertension  	 FW	I-NP
( 	( 	 -LRB-	O
PAH 	PAH 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
gain  	gain  	 VB	O
approval  	approval  	 NN	O
for  	for  	 IN	O
targeted  	targeted  	 JJ	O
therapies 	therapies 	 NNS	O
.  	.  	 .	O
Other  	Other  	 JJ	B-NP
biomarkers  	biomarkers  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
studied  	studied  	 VBN	O
to  	to  	 TO	O
overcome  	overcome  	 VB	O
certain  	certain  	 JJ	O
limitations  	limitations  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
walk  	walk  	 JJ	B-NP
test 	test 	 NN	I-NP
.  	.  	 .	O
Potential  	Potential  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
applications  	applications  	 NNS	I-NP
for  	for  	 IN	I-NP
biomarkers  	biomarkers  	 NN	I-NP
in  	in  	 IN	O
PAH  	PAH  	 NNP	B-NP
include  	include  	 VBP	O
screening 	screening 	 VBG	O
,  	,  	 ,	O
determination  	determination  	 NN	B-NP
of  	of  	 IN	O
prognosis 	prognosis 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
monitoring  	monitoring  	 VBG	B-NP
response  	response  	 NN	I-NP
to  	to  	 TO	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
Measurement  	Measurement  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
B-type  	B-type  	 JJ	B-NP
natriuretic  	natriuretic  	 JJ	I-NP
peptides  	peptides  	 NN	I-NP
is  	is  	 VBZ	O
currently  	currently  	 RB	O
recommended  	recommended  	 VBN	O
by  	by  	 IN	O
guidelines 	guidelines 	 NNS	O
,  	,  	 ,	O
despite  	despite  	 IN	O
a  	a  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
appropriate  	appropriate  	 JJ	O
validation  	validation  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
PAH  	PAH  	 NNP	B-NP
population 	population 	 NN	I-NP
.  	.  	 .	O
Novel  	Novel  	 NN	O
biomarkers  	biomarkers  	 VBZ	O
based  	based  	 VBN	O
on  	on  	 IN	O
recently  	recently  	 RB	O
discovered  	discovered  	 VBN	O
pathobiologic  	pathobiologic  	 JJ	B-NP
pathways  	pathways  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
identified 	identified 	 VBN	O
,  	,  	 ,	O
like  	like  	 IN	O
CXC  	CXC  	 NNP	O
chemokine  	chemokine  	 VBD	O
ligand  	ligand  	 CD	B-NP
10 	10 	 CD	O
,  	,  	 ,	O
C-reactive  	C-reactive  	 JJ	B-NP
protein 	protein 	 NN	I-NP
,  	,  	 ,	O
high-density  	high-density  	 JJ	B-NP
lipoprotein  	lipoprotein  	 JJ	I-NP
cholesterol  	cholesterol  	 NN	I-NP
and  	and  	 CC	O
growth-differentiation  	growth-differentiation  	 JJ	B-NP
factor-15 	factor-15 	 NN	I-NP
.  	.  	 .	O
Rigorous  	Rigorous  	 JJ	B-NP
statistical 	statistical 	 JJ	I-NP
,  	,  	 ,	O
biologic  	biologic  	 NN	B-NP
and  	and  	 CC	O
clinical  	clinical  	 JJ	B-NP
validation  	validation  	 NN	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
necessary  	necessary  	 JJ	O
before  	before  	 IN	O
any  	any  	 DT	O
biomarker  	biomarker  	 NN	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
endorsed  	endorsed  	 VBN	O
for  	for  	 IN	O
widespread  	widespread  	 JJ	O
clinical  	clinical  	 JJ	B-NP
use 	use 	 NN	I-NP
.  	.  	 .	O
